Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421013 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
A Phase 1 study, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05421013: Completed Phase 1 study, sponsored by Sirnaomics.
NCT05421013 is a Phase 1 study that has completed, run by Sirnaomics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421013, a Phase 1 study, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Open label, dose escalation to evaluate safety.
Primary Outcome
Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review
Interventions
- DRUG STP705
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 1 |
What the finished NCT05421013 record still lists
NCT05421013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which STP705 is the first listed.
NCT05421013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05421013 about?
NCT05421013 is a clinical study titled "Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC". Open label, dose escalation to evaluate safety.
What is the current status of trial NCT05421013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-08-01. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT05421013?
The interventions under investigation include: STP705 (DRUG).
Who is sponsoring clinical trial NCT05421013?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05421013's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI